These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

551 related articles for article (PubMed ID: 11352951)

  • 41. Preventing relapse beyond 5 years: the MA.17 extended adjuvant trial.
    Goss PE
    Semin Oncol; 2006 Apr; 33(2 Suppl 7):S8-12. PubMed ID: 16730271
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Efficacy of letrozole for advanced breast cancer in postmenopausal patients.
    Ansari TN; Mahmood A; Hussain I; Samad A
    J Coll Physicians Surg Pak; 2005 Apr; 15(4):204-6. PubMed ID: 15857590
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Reducing the risk for breast cancer recurrence after completion of tamoxifen treatment in postmenopausal women.
    Jahanzeb M
    Clin Ther; 2007 Aug; 29(8):1535-47. PubMed ID: 17919537
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Understanding the BIG results: Insights from the BIG 1-98 trial analyses.
    Wardley AM
    Adv Ther; 2008 Dec; 25(12):1257-75. PubMed ID: 19096768
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Aromatase inhibitors in advanced breast cancer.
    Mouridsen HT
    Semin Oncol; 2004 Dec; 31(6 Suppl 12):3-8. PubMed ID: 15719595
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer.
    ; Mouridsen H; Giobbie-Hurder A; Goldhirsch A; Thürlimann B; Paridaens R; Smith I; Mauriac L; Forbes J; Price KN; Regan MM; Gelber RD; Coates AS
    N Engl J Med; 2009 Aug; 361(8):766-76. PubMed ID: 19692688
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Letrozole vs. tamoxifen as neoadjuvant therapy for postmenopausal patients with hormone-dependent locally-advanced breast cancer].
    Novoa Vargas A; Font López KC; Amador DD
    Ginecol Obstet Mex; 2011 Sep; 79(9):553-7. PubMed ID: 21966856
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial.
    Osborne CK; Pippen J; Jones SE; Parker LM; Ellis M; Come S; Gertler SZ; May JT; Burton G; Dimery I; Webster A; Morris C; Elledge R; Buzdar A
    J Clin Oncol; 2002 Aug; 20(16):3386-95. PubMed ID: 12177098
    [TBL] [Abstract][Full Text] [Related]  

  • 49. An open randomised trial of second-line endocrine therapy in advanced breast cancer. comparison of the aromatase inhibitors letrozole and anastrozole.
    Rose C; Vtoraya O; Pluzanska A; Davidson N; Gershanovich M; Thomas R; Johnson S; Caicedo JJ; Gervasio H; Manikhas G; Ben Ayed F; Burdette-Radoux S; Chaudri-Ross HA; Lang R
    Eur J Cancer; 2003 Nov; 39(16):2318-27. PubMed ID: 14556923
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Systematic review of lapatinib in combination with letrozole compared with other first-line treatments for hormone receptor positive(HR+) and HER2+ advanced or metastatic breast cancer(MBC).
    Riemsma R; Forbes CA; Amonkar MM; Lykopoulos K; Diaz JR; Kleijnen J; Rea DW
    Curr Med Res Opin; 2012 Aug; 28(8):1263-79. PubMed ID: 22738819
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Letrozole as upfront endocrine therapy for postmenopausal women with hormone-sensitive breast cancer: BIG 1-98.
    Koeberle D; Thuerlimann B
    Breast Cancer Res Treat; 2007; 105 Suppl 1(Suppl 1):55-66. PubMed ID: 17912636
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Serum TIMP-1 and response to the aromatase inhibitor letrozole versus tamoxifen in metastatic breast cancer.
    Lipton A; Leitzel K; Chaudri-Ross HA; Evans DB; Ali SM; Demers L; Hamer P; Brown-Shimer S; Pierce K; Gaur V; Carney W
    J Clin Oncol; 2008 Jun; 26(16):2653-8. PubMed ID: 18443351
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Changing clinical practice: extending the benefits of adjuvant endocrine therapy in breast cancer.
    Goss PE
    Semin Oncol; 2004 Dec; 31(6 Suppl 12):15-22. PubMed ID: 15719597
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Endocrine effects of adjuvant letrozole compared with tamoxifen in hormone-responsive postmenopausal patients with early breast cancer: the HOBOE trial.
    Rossi E; Morabito A; Di Rella F; Esposito G; Gravina A; Labonia V; Landi G; Nuzzo F; Pacilio C; De Maio E; Di Maio M; Piccirillo MC; De Feo G; D'Aiuto G; Botti G; Chiodini P; Gallo C; Perrone F; de Matteis A
    J Clin Oncol; 2009 Jul; 27(19):3192-7. PubMed ID: 19380451
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Quality-adjusted survival in a crossover trial of letrozole versus tamoxifen in postmenopausal women with advanced breast cancer.
    Irish W; Sherrill B; Cole B; Gard C; Glendenning GA; Mouridsen H
    Ann Oncol; 2005 Sep; 16(9):1458-62. PubMed ID: 15946978
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Exemestane versus anastrozole as front-line endocrine therapy in postmenopausal patients with hormone receptor-positive, advanced breast cancer: final results from the Spanish Breast Cancer Group 2001-03 phase 2 randomized trial.
    Llombart-Cussac A; Ruiz A; Antón A; Barnadas A; Antolín S; Alés-Martínez JE; Alvarez I; Andrés R; García Saenz JA; Lao J; Carrasco E; Cámara C; Casas I; Martín M
    Cancer; 2012 Jan; 118(1):241-7. PubMed ID: 21717449
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Efficacy and safety of endocrine monotherapy as first-line treatment for hormone-sensitive advanced breast cancer: A network meta-analysis.
    Zhang J; Huang Y; Wang C; He Y; Zheng S; Wu K
    Medicine (Baltimore); 2017 Aug; 96(33):e7846. PubMed ID: 28816986
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Lapatinib plus letrozole as first-line therapy for HER-2+ hormone receptor-positive metastatic breast cancer.
    Schwartzberg LS; Franco SX; Florance A; O'Rourke L; Maltzman J; Johnston S
    Oncologist; 2010; 15(2):122-9. PubMed ID: 20156908
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Approval summary: letrozole (Femara® tablets) for adjuvant and extended adjuvant postmenopausal breast cancer treatment: conversion of accelerated to full approval.
    Cohen MH; Johnson JR; Justice R; Pazdur R
    Oncologist; 2011; 16(12):1762-70. PubMed ID: 22089970
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Extended adjuvant intermittent letrozole versus continuous letrozole in postmenopausal women with breast cancer (SOLE): a multicentre, open-label, randomised, phase 3 trial.
    Colleoni M; Luo W; Karlsson P; Chirgwin J; Aebi S; Jerusalem G; Neven P; Hitre E; Graas MP; Simoncini E; Kamby C; Thompson A; Loibl S; Gavilá J; Kuroi K; Marth C; Müller B; O'Reilly S; Di Lauro V; Gombos A; Ruhstaller T; Burstein H; Ribi K; Bernhard J; Viale G; Maibach R; Rabaglio-Poretti M; Gelber RD; Coates AS; Di Leo A; Regan MM; Goldhirsch A;
    Lancet Oncol; 2018 Jan; 19(1):127-138. PubMed ID: 29158011
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 28.